Drug evaluation: ISIS-301012, an antisense oligonucleotide for the treatment of hypercholesterolemia

John R Burnett

Drug evaluation: ISIS-301012, an antisense oligonucleotide for the treatment of hypercholesterolemia

Curr Opin Mol Ther. 2006 Oct;8(5):461-7.

Author

John R Burnett¹

Affiliation

¹ Royal Perth Hospital, Department of Core Clinical Pathology and Biochemistry, PathWest Laboratory Medicine WA, Wellington Street, GPO Box X2213, Perth, WA 6847, Australia. john.burnett@health.wa.gov.au

PMID: 17078389

Abstract

ISIS-301012 is an antisense oligonucleotide inhibitor of apolipoprotein B-100, which is being developed by Isis Pharmaceuticals Inc for the potential treatment of hypercholesterolemia. A subcutaneous injectable formulation is currently undergoing phase 11 clinical trials, while phase I trials are underway with an oral formulation of the drug.

Publication types

Review

MeSH terms

Apolipoprotein B-100 / genetics*
Clinical Trials, Phase I as Topic
Clinical Trials, Phase II as Topic
Humans
Hypercholesterolemia / drug therapy*
Oligonucleotides, Antisense / adverse effects
Oligonucleotides, Antisense / therapeutic use*

Substances

Apolipoprotein B-100
Oligonucleotides, Antisense